Cassava Sciences | PTIE - Ebitda


Cassava Sciences reported $-11.73M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Amgen USD 3.86B 1.28B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Eisai JPY 34.15B 34.48B Jun/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Geron USD 3.83M 25.12M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.01B 18M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026